Results 21 to 30 of about 34,967 (216)

Real-world experience in managing atrial fibrillation in patients with renal impairment; Rivaroxaban versus warfarin

Heart Views, 2023
Background: The use of rivaroxaban in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) poses the risk of over- or underdosing. We aimed to compare rivaroxaban and warfarin in AF patients with moderate and severe renal impairment ...
Monirah Abdulrahman Albabtain, Zaid Dakheel Alanazi, Nawaf Hamoud Al-Mutairi, Ola Alyafi, Raneem Albanyan, Amr A Arafat   +5 more
doaj   +1 more source

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation [PDF]

, 2014
A John Camm,1 Pierre Amarenco,2 Sylvia Haas,3 Susanne Hess,4 Paulus Kirchhof,5,6 Martin van Eickels,4 Alexander GG Turpie71Division of Clinical Sciences, St George's, University of London, London, UK; 2Department of Neurology and Stroke Center, Paris-
Hess, S, Camm, AJ, Amarenco, Pierre, Eickels MV, Turpie, AG, Hess, Susanne, Haas, S, Turpie, Alexander G G, Kirchhof, P, van Eickels, M, Haas, Sylvia, Kirchhof, Paulus; id_orcid, Amarenco, P, Camm AJ, Hess S, Camm, John, Amarenco P, Van Eickels, Martin, Turpie AGG, Kirchhof P, Haas S   +20 more
core   +1 more source

Rivaroxaban prescribing in a Saudi tertiary care teaching hospital

Saudi Pharmaceutical Journal, 2018
Purpose: This drug utilization review (DUR) aimed to describe the use of rivaroxaban in a tertiary care teaching hospital and to audit the hospital physicians’ prescribing practice.
Ahmed Yacoob Mayet, Ahmed Ibrahim Alsaqer, Abdullah Musa Alhammad, Hussain Abdulrahman Al-Omar   +3 more
doaj   +1 more source

Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study

BMC Pharmacology and Toxicology, 2020
Background Rivaroxaban, a novel oral anticoagulant drug, is widely used in clinical practice. There is no standardized laboratory monitoring for rivaroxaban, and its plasma concentration in Chinese patients with deep vein thrombosis is unclear.
Ying Li, Liping Du, Xiaowan Tang, Yuexin Chen, Dan Mei   +4 more
doaj   +1 more source

Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice [PDF]

, 2018
Kavitha Vimalesvaran,1 Seth J Dockrill,1 Diana A Gorog1–3 1Department of Cardiology, East and North Hertfordshire NHS Trust, Stevenage, Hertfordshire, UK; 2School of Life and Medical Sciences, Postgraduate Medical School, University of ...
Gorog DA, Diana A Gorog, Seth Dockrill, Kavitha Vimalesvaran, Vimalesvaran K, Gorog, Diana, Vimalesvaran, Kavitha, Dockrill SJ, Dockrill, Seth J   +8 more
core   +1 more source

Rivaroxaban Induced Hallucinations: A Case Report [PDF]

, 2022
Hallucinations induced by rivaroxaban are not much described in literature. This case report describes the occurrence of a specific adverse event during rivaroxaban use in an elderly male who developed hallucinations few months after starting rivaroxaban.
Matthew Ferguson, Anshika Balwan
core   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ, Bounameaux, H, A. John Camm, Henri Bounameaux   +3 more
core   +1 more source

Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. [PDF]

, 2021
AIMS To investigate the influence of a cytochrome P450 CYP3A4 and efflux transporter P-glycoprotein (P-gp) inducing Hypericum perforatum extract on the pharmacokinetics and pharmacodynamics of rivaroxaban.
Urs Duthaler, Manuel Haschke, Katharina Elisabeth Grafinger, Grafinger, Katharina Elisabeth, Evangelia Liakoni, Stephan Krähenbühl, Michael Nagler, Irene Scholz, Krähenbühl, Stephan, Nagler, Michael, Haschke, Manuel, Felix Hammann, Hammann, Felix, Scholz, Irene, Liakoni, Evangelia, Duthaler, Urs   +15 more
core   +1 more source

Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice

Scientific Reports, 2017
Rivaroxaban is an oral direct factor Xa inhibitor approved for the treatment of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation. Despite its efficacy, rivaroxaban therapy results in adverse effects and complications,
Dan Yang, Junjie Shao, Ruifeng Hu, Haimei Chen, Ping Xie, Chang Liu   +5 more
doaj   +1 more source

Update on Rivaroxaban

, 2010
Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE). The new anticoagulants which target specific factors in the coagulation cascade offer the advantage that they can be administered orally. These drugs seek to
Dipankar Chattopadhyay, Osama Moussa, Vish Bhattacharya   +2 more
core   +1 more source